AIMS: C-reactive protein (CRP) is a predictor of many diseases including type II diabetes and cardiovascular disease. Fewer studies have similarly shown sialic acid (SA) to be a predictor of obesity-related diseases, but importantly SA shows less intraindividual variability than CRP and acts as an integrated marker of the activity of a number of acute-phase proteins. This study examines the association between both CRP and SA with individual and combined features of the metabolic syndrome. SUBJECTS: In all, 257 women with a body mass index (BMI) ranging from 25.1 to 54.5 kg/m 2 (geometric mean 33.175.8 kg/m 2 ) and aged 19-71 y (mean 45.6712.1 y) were studied. Subjects had no symptoms of intercurrent infection, known diabetes, treated dyslipidaemia, a chronic inflammatory condition, liver disease or malignancy. RESULTS: Linear regression demonstrates that both CRP and SA were positively associated with weight, BMI, insulin resistance, dyslipidaemia and hypertension. There was a highly significant (Po0.0001) positive association of both SA and CRP with none, one, two, three or four features of the metabolic syndrome. For a 1 s.d. (4.0 mg/l) increase in CRP, there was a significant increased risk when comparing the odds of having metabolic syndrome (defined as three or more individual features) compared with the remainder of the population (odds ratio ¼ 1.7, Po0.0001), but this was not significant after adjustment for BMI. However, for a 1 s.d. (0.34 mmol/l) increase in SA, the odds of having metabolic syndrome compared with those without metabolic syndrome was 2.5 (Po0.0001), and persisted after additional adjustment for BMI (adjusted odds ratio ¼ 1.9, Po0.0001). CONCLUSIONS: While SA and CRP are both univariately associated with individual features of the metabolic syndrome, SA, but not CRP, is significantly associated with the metabolic syndrome, independent of BMI. We conclude that SA identifies a subgroup of overweight individuals with an inflammatory phenotype, who are at the greatest risk of metabolic syndrome.
Introduction
There are strong links between obesity and the metabolic syndrome 1 and numerous mechanisms have been proposed to account for this relationship, including abnormal lipid metabolism, 2 autonomic nervous system effects 3 and hormonal factors resulting from an altered hypothalamicpituitary-adrenal axis. 4, 5 Emerging evidence has also identified a role for inflammatory mediators. 6 C-reactive protein (CRP), measured with a high-sensitivity assay as a marker of low-grade inflammation, is the most widely studied acute-phase protein. Cross-sectional studies have shown that CRP is related to diseases including cardiovascular disease and type II diabetes. Prospective studies have shown that CRP is also an independent predictor of both cardiovascular disease 7, 8 and type II diabetes. [9] [10] [11] There is limited evidence of an incremental relationship between CRP and features of the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. 12 However, CRP is also related to obesity, 13, 14 which itself is a strong predictor of disease. 1 Most studies investigating the relationship between inflammation and obesity-related disease do not adjust for body mass index (BMI) in their analyses. Other studies, once adjusted for BMI, show that CRP is no longer independently related to their outcome. 10 CRP is also greatly affected by acute inflammatory events, where concentrations can be rapidly elevated. This makes it a clinically useful marker of acute illness, but makes measurement of habitual inflammatory status using CRP concentrations difficult to interpret. We have recently shown that sialic acid (SA) has less intra-individual variability over time in weight-stable subjects than other potential markers of inflammation including CRP, and may provide a more robust measure of habitual inflammatory status. 15 SA (or Nacetylneuraminic acid) forms the terminal component of many acute-phase proteins such as a 1 -antichymotrypsin, a 1 -antitrypsin, haptoglobin and orosomucoid, and these glycoproteins together explain 70% of the total serum SA concentration. 16 In addition to being the most stable acute-phase marker, SA may also be a useful indicator of the overall acute-phase response. In the same way as CRP, SA has been shown to be associated with and a predictor of cardiovascular disease 17 and type II diabetes. 18 In the Atherosclerosis Risk in Communities study, individuals with a SA concentration above the median were four times more likely to have type II diabetes 7 y later, than those below the median. This study examines the relationship between both serum CRP and SA concentrations and the occurrence of individual and combined features of the metabolic syndrome in an overweight population to further investigate the role of inflammation in the pathogenesis of type II diabetes and cardiovascular disease.
Methods

Population
The 257 subjects included in this study had been recruited from the community to participate in two nutritional intervention studies being undertaken at MRC Human Nutrition Research. The studies were approved by the local research ethics committee, and all subjects gave written informed consent. The data reported are from the initial medical examination and screening blood test taken as part of those studies. Female subjects were included in the present analysis if they had a BMI greater than 25 kg/m 2 , and did not have symptoms of an intercurrent infection, known diabetes, treated dyslipidaemia, a chronic inflammatory condition, liver disease or malignancy. In addition, subjects were excluded if they had a CRP concentration greater than 20 mg/l, smoked more than 25 cigarettes per day or had an alcohol intake of greater than 25 U/week.
Data collection
Blood was collected between 0800 and 1000 h after an overnight fast of at least 12 h. The samples were kept on ice and centrifuged at 3000 rpm for 20 min within an hour of collection, aliquoted and frozen at À801C until analysed. Total serum SA was assayed using a colorimetric enzymatic method (Roche, Welwyn Garden City, UK) as previously described, 19 Dyslipidaemia was defined as a fasting triglyceride concentration greater than 1.7 mmol/l (150 mg/dl) or a fasting high-density lipoprotein (HDL) cholesterol concentration less than 1.0 mmol/l. Since all individuals were at increased risk of insulin resistance, using the highest quartile would not be appropriate in this study population. Insulin resistance was defined as a fasting insulin concentration above 60 pmol/l or a fasting glucose concentration greater than 6.1 mmol/l. The number of features of metabolic syndrome was defined by the combination of central obesity, hypertension, dyslipidaemia or insulin resistance, and ranged from none to four features. The definition for metabolic syndrome was three or more individual features as defined above.
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Statistical analysis
Simple linear regression (for continuous explanatory variables such as age, weight and waist circumference) was used to investigate the relationship between CRP or SA concentration (outcome variable) and the selected subject characteristics. In order to reduce the skewness of some of the distributions, the corresponding variables were log e -transformed prior to analysis. Geometric means are presented for transformed variables. Differences between individuals, grouped based on the number of features of the metabolic syndrome, were tested using analysis of variance (ANOVA), with Bonferroni's adjustment for multiple comparisons.
For both CRP and SA, adjusted odds ratios (OR) and 95% confidence intervals were estimated for the risk of having the metabolic syndrome (defined as three or more individual features) as compared to the remainder of the population (those with less than three individual features) using multiple logistic regression. The odds ratios obtained were adjusted for potential confounders (Model 2): age, cigarette-smoking status, alcohol consumption status, menopausal status, oral contraceptive and HRT use. In the final model (Model 3), these odds ratios were further adjusted for BMI. Crude and adjusted odds ratios were obtained using Proc Logistic in SAS.
Results
The 257 overweight and obese women had a BMI range from 25.1 to 54.5 kg/m 2 (geometric mean 33.575.7 kg/m 2 ) and were aged 19-71 y (mean 45.5712.1 y). A summary of relevant subject characteristics is shown in Table 1 . In all, 24 subjects reported smoking, and 44 subjects reported alcohol intake of between 10 and 25 U/week. In all, 151 women were pre-menopausal, with 31 taking the oral contraceptive (OC), and 106 post-menopausal, with 35 taking hormone replacement therapy (HRT).
Post-menopausal women had higher CRP and SA concentrations than pre-menopausal women (geometric mean 2.75 vs 1.92 mg/l, P ¼ 0.022, and mean 2.36 vs 2.26 mmol/l, P ¼ 0.024). In addition, OC use in pre-menopausal women increased CRP and SA (geometric mean 4.64 vs 1.53 mg/l, Po0.0001, and mean 2.42 vs 2.22 mmol/l, P ¼ 0.006), and HRT use in post-menopausal women increased CRP (geometric mean 3.76 vs 2.36 mg/l, P ¼ 0.039) but not SA (mean 2.35 vs 2.37 mmol/l). Moderate alcohol consumption did not affect CRP concentrations (geometric mean 1.65 vs 2.37 mg/ l), but reduced SA concentrations (mean 2.16 vs 2.33 mmol/l, Po0.0001). Smoking had no effect on CRP or SA concentrations (geometric mean 2.22 vs 2.35 mg/l and mean 2.29 vs 2.39 mmol/l). Adjustment for all these variables (Table 2) was therefore made in subsequent analyses.
Regression of SA on body weight and abdominal fatness (estimated by waist circumference), insulin resistance (fasting insulin or HOMA), dyslipidaemia (triglyceride or HDL cholesterol) and systolic blood pressure (adjusted for age, menopausal status, OC or HRT use, smoking and alcohol intake) demonstrated strong relationships between SA and each of these features of the metabolic syndrome (Po0.0001 for all, Table 3 ). Regression analysis of CRP showed similar (Table 3) . However, diastolic blood pressure was not significantly related to CRP or SA in the analysis. ANOVA showed a number of significant differences in metabolic parameters between groups based on the number of individual features of the metabolic syndrome (Table 4 ). Figure 1 shows mean CRP concentrations in subjects according to the presence or absence of individual features of the metabolic syndrome. An incremental increase in CRP is shown with increasing occurrence of these features (standardized b ¼ 0.41, Po0.0001). Once adjusted for BMI, CRP is no longer associated with incremental features of the metabolic syndrome (standardized b ¼ 0.10, P ¼ 0.1). Table 5 shows the results from the ordinal logistic regression models. Sialic acid, CRP and the metabolic syndrome LM Browning et al As CRP concentrations increased by 1 s.d. (4.0 mg/l), there was a significant increased risk when comparing the odds of having metabolic syndrome (defined as three or more individual features) with the remainder of the population (those with less than three individual features), odds ratio ¼ 1.7, Po0.0001, model 2. However, when the model was further adjusted for BMI, there was no significant increased risk of metabolic syndrome (Model 3, Table 5 ). Figure 2 shows a significant incremental association between SA and individual features of the metabolic syndrome (standardized b ¼ 0.31, Po0.0001), which remains significant after adjustment for BMI (standardized b ¼ 0.24, Po0.0001). As SA concentrations increased by 1 s.d. (0.34 mmol/l), the adjusted odds of having the metabolic syndrome relative to the remainder of the population was 2.5 times (Po0.0001, Model 2, Table 5 ). In model 3, after adjustment for BMI, the increased risk of the metabolic syndrome persisted. For a 1 s.d. increase in SA, equivalent to 0.34 mmol/l, the odds ratio for having metabolic syndrome compared to the remainder of the population was 1.9 times (Po0.0001).
Discussion
We have confirmed that both CRP and SA are associated with incremental features of the metabolic syndrome, but importantly this analysis shows that SA, but not CRP, is an independent predictor after adjustment for BMI. This contradicts the study by Festa et al, 12 who showed that CRP was incrementally associated with features of the metabolic syndrome in a population of 1008 subjects even after adjustment for BMI. SA was not measured in this study. There may be a number of reasons for the disparity between SA and CRP in our data. Firstly, it may be explained by the relative biological stabilities of the acute-phase markers. Despite using a high-sensitivity assay for CRP, we have shown that SA is a more stable inflammatory marker, and therefore provides a more accurate reflection of an individual's habitual inflammatory status. 15 The relative instability in CRP may explain why, in a larger population, 12 there is a significant relationship between CRP and metabolic syndrome features even after adjustment for BMI. Secondly, SA acts as an integrated marker of a number of acute-phase proteins and is representative of the overall acute-phase response, whereas CRP is simply one of a number of acute-phase proteins that may be released from the liver as part of an inflammatory process. Differences between CRP and SA in their relationships with individual features of the metabolic syndrome may also be important.
In Table 3 , SA shows a stronger relationship with the hypertension-and dyslipidaemia-related factors than CRP. In Table 4 , there is no further significant increase in CRP with two, three or four features. SA, however, continues to significantly increase across these groups. Individuals in the group with one feature predominantly have the obesity feature, perhaps suggesting that CRP is strongly associated with obesity and that individuals show no further increase in CRP as they accumulate additional metabolic risk. This study confirms a significant relationship between inflammation and metabolic disease. Previous studies have demonstrated that a raised background inflammatory state, as reflected by markers such as SA, CRP and fibrinogen, is associated with cardiovascular disease and diabetes. 17, 19, 16, 22, 18, 23 What remains unclear is whether this relationship is causal. Inflammation may result from metabolic disease, or it may be directly involved in the pathogenesis of the metabolic syndrome. Alternatively, the association may represent a bystander effect in which SA and CRP act as markers of other pathogenic processes. Although inflammation is a strong predictor of metabolic disease, [7] [8] [9] [10] [11] supporting a causal role, biological evidence for a direct pathogenic role for acute-phase markers is limited. SA is an important component in cell membranes 24 and has the potential to influence cell membrane function, including transport and receptor function. CRP may affect the expression of a number of molecules including endothelin-1 and IL-6. 25, 26 However, direct evidence for a functional effect of either CRP or SA on the insulin receptor or GLUT-4 glucose transporter is lacking. Regarding dyslipidaemia, many apolipoproteins contain SA, which may influence the behaviour of the associated lipoproteins, 27 and changes in sialylation of LDL particles in particular have been linked with atherosclerosis. 28, 29 Increased SA content of VLDL particles may contribute to hypertriglyceridaemia. 30 CRP may also have a direct effect on dyslipidaemia by mediating the uptake of LDL by macrophages. 31 Although these mechanisms may explain in part the relationship between acute-phase markers and the metabolic syndrome, they are unlikely to be the only factors. CRP and SA may also be markers of the pathogenic process. Adipocyte-derived cytokines, IL-6 and TNF-a, may contribute Sialic acid, CRP and the metabolic syndrome LM Browning et al to the insulin resistance and dyslipidaemia in obesity by interfering with insulin signaling and glucose transport, and with lipid metabolism and triglyceride clearance. 32, 23 As part of their pleiotropic actions, these cytokines act to elevate CRP and SA concentration by promoting acute-phase protein production by the liver. 33 Alternatively, obesity may be the underlying process, although the pathogenic link between adipose tissue and the metabolic syndrome is yet to be fully determined. While whole body insulin resistance is widely regarded as central to the process, the actual mechanism for the development of insulin resistance is not clear. There is evidence that increased output of nonesterified fatty acids from adipose tissue in obese subjects contributes to insulin resistance. 2 Similarly, hyperinsulinaemia associated with obesity may increase sympathetic nervous system activity, which has been linked with hypertension and dyslipidaemia.
3 Dysregulation of the hypothalamic-pituitary-adrenal axis has also been proposed as a mediator of the association between obesity and the metabolic syndrome. 5 There is increasing evidence that excess adipose tissue, acting as an endocrine organ, produces and secretes circulating factors which may act at distant sites to promote insulin resistance, atherosclerosis, hypertension and dyslipidaemia, providing another potential mechanism. Possible candidates for this factor(s) include IL-6, TNFa, resistin, leptin and plasminogen activator inhibitor-1 (PAI-1). 34 Importantly, not all obese individuals develop co-morbid diseases such as type II diabetes or cardiovascular disease. We have shown that the relationship between habitual inflammatory status and metabolic disease persists after adjustment for BMI and this may identify overweight individuals at high metabolic risk. It has been proposed that cardiovascular disease and type II diabetes may be caused in part by a 'thrifty genotype', which improves an individuals chance of survival during times of famine, but becomes disadvantageous in a plentiful environment, and associated obesity, or a 'thrifty phenotype' where events in early life may predispose an individual to later disease. 35 It has also been suggested that a 'pro-inflammatory genotype' may allow an individual to better defend itself against pathogens during times of famine, but becomes disadvantageous in times of plenty. 36 Thus, an 'inflammatory phenotype' is linked not only with obesity, but also independently with the risk of cardiovascular disease in an obese population. This is consistent with the hypothesis that individuals with a 'pro-inflammatory genotype' may be more susceptible to disease when obese, and may begin to explain why some, but not all, overweight individuals develop disease. Acute-phase markers such as SA and CRP are important both clinically and in research as integrated and distal markers of cytokine activity, taking into account the influence of a number of inflammatory genes. This study suggests that CRP may not reflect the true relationship between inflammation and metabolic risk, while SA, a more stable and perhaps more representative marker of the overall acute-phase response, may be a more appropriate acutephase marker to study in obesity-related disease.
